| Generic name | Lisocabtagene maraleucel |
| Brand name(s), other common name(s) | Breyanzi® |
| Drug type | CD19-directed genetically modified autologous T cell immunotherapy |
| How the drug is given | Intravenously (IV) |
Indications and Usage
Lisocabtagene maraleucel is FDA approved for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (including DLBCL arising from indolent lymphoma), high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B.
Limitations of Use: Breyanzi is not indicated for the treatment of patients with primary central nervous system lymphoma.
Side effects needing medical attention
The most common adverse reactions in Breyanzi-treated patients were fatigue, cytokine release syndrome, musculoskeletal pain, nausea, headache, encephalopathy (damage or disease that affects the brain) , infections, decreased appetite, diarrhea, low blood pressure (hypotension), tachycardia (heart rate over 100 beats per minute), dizziness, cough, constipation, abdominal pain, vomiting, and edema (swelling).
For information on how to manage the costs of drug therapy, please see Financial Support, or to speak with an Information Specialist, call (800) 955-4572.